Robert Shafer
Robert Shafer
Professor of Medicine, Stanford University
Verified email at - Homepage
Cited by
Cited by
2011 update of the drug resistance mutations in HIV-1
VA Johnson, V Calvez, HF GŁnthard, R Paredes, D Pillay, R Shafer, ...
Topics in antiviral medicine 19 (4), 156, 2011
Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update
DE Bennett, RJ Camacho, D Otelea, DR Kuritzkes, H Fleury, M Kiuchi, ...
PloS one 4 (3), e4724, 2009
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
International HIV Controllers Study
Science 330 (6010), 1551-1557, 2010
2017 update of the drug resistance mutations in HIV-1
AM Wensing, V Calvez, HF GŁnthard, VA Johnson, R Paredes, D Pillay, ...
Topics in antiviral medicine 24 (4), 132, 2016
Human immunodeficiency virus reverse transcriptase and protease sequence database
SY Rhee, MJ Gonzales, R Kantor, BJ Betts, J Ravela, RW Shafer
Nucleic acids research 31 (1), 298-303, 2003
The biological and clinical significance of emerging SARS-CoV-2 variants
K Tao, PL Tzou, J Nouhin, RK Gupta, T de Oliveira, SL Kosakovsky Pond, ...
Nature Reviews Genetics 22 (12), 757-773, 2021
Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection
PM Small, RW Shafer, PC Hopewell, SP Singh, MJ Murphy, ED Desmond, ...
New England Journal of Medicine 328 (16), 1137-1144, 1993
Web resources for HIV type 1 genotypic-resistance test interpretation
TF Liu, RW Shafer
Clinical infectious diseases 42 (11), 1608-1618, 2006
Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance
C Wang, Y Mitsuya, B Gharizadeh, M Ronaghi, RW Shafer
Genome research 17 (8), 1195-1201, 2007
HIV-1 antiretroviral resistance: scientific principles and clinical applications
MW Tang, RW Shafer
Drugs 72, e1-e25, 2012
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection
GK Robbins, V De Gruttola, RW Shafer, LM Smeaton, SW Snyder, ...
New England Journal of Medicine 349 (24), 2293-2303, 2003
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART
RW Shafer, JM Schapiro
AIDS reviews 10 (2), 67, 2008
Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection
RW Shafer, DS Kim, JP Weiss, JM Quale
Medicine 70 (6), 384-397, 1991
Rationale and uses of a public HIV drug‐resistance database
RW Shafer
The Journal of infectious diseases 194 (Supplement_1), S51-S58, 2006
Genotypic testing for human immunodeficiency virus type 1 drug resistance
RW Shafer
Clinical microbiology reviews 15 (2), 247-277, 2002
HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance
RW Shafer, SY Rhee, D Pillay, V Miller, P Sandstrom, JM Schapiro, ...
Aids 21 (2), 215-223, 2007
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
R Kantor, DA Katzenstein, B Efron, AP Carvalho, B Wynhoven, P Cane, ...
PLoS medicine 2 (4), e112, 2005
HIV-1 drug resistance and resistance testing
DS Clutter, MR Jordan, S Bertagnolio, RW Shafer
Infection, Genetics and Evolution 46, 292-307, 2016
Genotypic predictors of human immunodeficiency virus type 1 drug resistance
SY Rhee, J Taylor, G Wadhera, A Ben-Hur, DL Brutlag, RW Shafer
Proceedings of the National Academy of Sciences 103 (46), 17355-17360, 2006
Update of the drug resistance mutations in HIV-1: March 2013
VA Johnson, V Calvez, HF GŁnthard, R Paredes, D Pillay, RW Shafer, ...
Topics in antiviral medicine 21 (1), 6, 2013
The system can't perform the operation now. Try again later.
Articles 1–20